

# Rita De Santis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4807078/publications.pdf>

Version: 2024-02-01

61  
papers

2,364  
citations

304368

22  
h-index

205818

48  
g-index

65  
all docs

65  
docs citations

65  
times ranked

3184  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. <i>Molecular Therapy</i> , 2022, 30, 1979-1993.	3.7	15
2	Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition. <i>Chemical Communications</i> , 2021, 57, 867-870.	2.2	7
3	Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. <i>MAbs</i> , 2020, 12, 1725346.	2.6	16
4	Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3248-3253.	1.4	8
5	ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1. <i>Frontiers in Oncology</i> , 2019, 9, 1534.	1.3	9
6	Therapeutic efficacy of intra-tumor AvidinOX and low systemic dose biotinylated cetuximab, with and without cisplatin, in an orthotopic model of head and neck cancer. <i>Oncology Letters</i> , 2019, 17, 3529-3536.	0.8	0
7	Characterization of therapeutic protein AvidinOX by an integrated analytical approach. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 553-564.	1.9	3
8	Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3312-3314.	1.0	2
9	Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation. <i>Chemical Science</i> , 2018, 9, 6490-6496.	3.7	20
10	Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 368-379.	2.6	14
11	Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. <i>Oncotarget</i> , 2018, 9, 9766-9775.	0.8	9
12	AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies. <i>Oncotarget</i> , 2017, 8, 22590-22605.	0.8	6
13	Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer. <i>Oncotarget</i> , 2016, 7, 914-928.	0.8	5
14	Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. <i>Oncology Reports</i> , 2015, 34, 1146-1152.	1.2	8
15	Radionuclide Therapy of Unresectable Tumors with AvidinOX and 90Y-biotinDOTA: Tongue Cancer Paradigm. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 291-298.	0.7	10
16	Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. <i>Oncotarget</i> , 2015, 6, 5735-5748.	0.8	16
17	PTX3 Binds MD-2 and Promotes TRIF-Dependent Immune Protection in Aspergillosis. <i>Journal of Immunology</i> , 2014, 193, 2340-2348.	0.4	49
18	Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. <i>Oncotarget</i> , 2014, 5, 9239-9255.	0.8	11

#	ARTICLE	IF	CITATIONS
19	Simultaneous display of two large proteins on the head and tail of bacteriophage lambda. <i>BMC Biotechnology</i> , 2013, 13, 79.	1.7	17
20	Effect of PTX3 and Voriconazole Combination in a Rat Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6400-6402.	1.4	19
21	Chemical Linkage to Injected Tissues Is a Distinctive Property of Oxidized Avidin. <i>PLoS ONE</i> , 2011, 6, e21075.	1.1	10
22	Preclinical Pharmacology and Safety of a Novel Avidin Derivative for Tissue-Targeted Delivery of Radiolabelled Biotin. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 145-155.	1.2	10
23	Anti-proliferative effect of a triazole derivative (ST1959) on LNCaP human prostate cancer cells through down-regulation of cyclin and androgen receptor expression. <i>Prostate</i> , 2011, 71, 32-41.	1.2	3
24	Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with <sup>90</sup> Y-labeled biotin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 203-211.	3.3	34
25	Efficacy of PTX3 in a Rat Model of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4513-4515.	1.4	32
26	Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody. <i>Journal of Biological Chemistry</i> , 2010, 285, 36149-36157.	1.6	73
27	Therapeutic Use of Avidin Is Not Hampered by Antiavidin Antibodies in Humans. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 563-570.	0.7	39
28	AvidinOX <sub>2</sub> for Highly Efficient Tissue-Pretargeted Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 143-148.	0.7	20
29	Biochemical and Biological Characterization of a New Oxidized Avidin with Enhanced Tissue Binding Properties. <i>Journal of Biological Chemistry</i> , 2010, 285, 9090-9099.	1.6	29
30	Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. <i>Rheumatology</i> , 2010, 49, 2281-2289.	0.9	78
31	Identification of Critical Residues of the MyD88 Death Domain Involved in the Recruitment of Downstream Kinases. <i>Journal of Biological Chemistry</i> , 2009, 284, 28093-28103.	1.6	77
32	OXavidin for Tissue Targeting Biotinylated Therapeutics. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-9.	3.0	13
33	Design, Synthesis, and In Vitro Activity of Peptidomimetic Inhibitors of Myeloid Differentiation Factor 88. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1189-1202.	2.9	28
34	Structural Characterization of PTX3 Disulfide Bond Network and Its Multimeric Status in Cumulus Matrix Organization. <i>Journal of Biological Chemistry</i> , 2008, 283, 10147-10161.	1.6	121
35	Efficacy of a Nanocholate-Encapsulated 3,5-Diaryl-s-Triazole Derivative in a Murine Model of Graft-Versus-Host Disease. <i>Transplantation</i> , 2008, 86, 171-175.	0.5	7
36	Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5646s-5651s.	3.2	22

#	ARTICLE	IF	CITATIONS
37	Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. <i>Journal of Leukocyte Biology</i> , 2007, 82, 801-810.	1.5	162
38	Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. <i>BMC Biotechnology</i> , 2007, 7, 70.	1.7	61
39	Dissecting drug and vehicle metabolic effects in rats by a metabonomic approach. <i>Journal of Proteomics</i> , 2007, 70, 355-361.	2.4	4
40	Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma. <i>European Journal of Haematology</i> , 2007, 79, 258-262.	1.1	10
41	Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRITÄ®). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 68-77.	3.3	42
42	Structure and Function of the Long Pentraxin PTX3 Glycosidic Moiety: Fine-Tuning of the Interaction with C1q and Complement Activation. <i>Biochemistry</i> , 2006, 45, 11540-11551.	1.2	113
43	Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. <i>Blood</i> , 2006, 108, 3387-3396.	0.6	130
44	Identification and refinement of a peptide affinity ligand with unique specificity for a monoclonal anti-tenascin-C antibody by screening of a phage display library. <i>Journal of Chromatography A</i> , 2006, 1107, 182-191.	1.8	17
45	Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. <i>BMC Cancer</i> , 2006, 6, 41.	1.1	30
46	Low and High Tenascin-Expressing Tumors Are Efficiently Targeted by ST2146 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2006, 12, 2191-2196.	3.2	26
47	Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies. <i>Clinical Cancer Research</i> , 2005, 11, 7137s-7145s.	3.2	33
48	Role of IL-6 and CD23 in the resistance to growth arrest and apoptosis in LCL41 B lymphoma cells. <i>Cytokine</i> , 2005, 31, 314-323.	1.4	2
49	Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. <i>Cytokine</i> , 2005, 31, 368-374.	1.4	12
50	Anti-Aspergillus fumigatus Efficacy of Pentraxin 3 Alone and in Combination with Antifungals. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4414-4421.	1.4	125
51	Antibody-based cancer therapies: back to "copolyclonals"? <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1453-1455.	3.3	4
52	Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. <i>Nature</i> , 2002, 420, 182-186.	13.7	636
53	The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis. <i>Experimental Hematology</i> , 2000, 28, 490-498.	0.2	10
54	Purification and characterization of two recombinant human granulocyte colony-stimulating factor glycoforms. <i>Molecular Biotechnology</i> , 1999, 11, 117-128.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors. <i>Experimental Hematology</i> , 1999, 27, 416-424.	0.2	18
56	Overproduction of soluble, extracellular cytotoxin $\hat{\pm}$ -sarcin in <i>Escherichia coli</i> . <i>Molecular Biotechnology</i> , 1998, 9, 99-106.	1.3	6
57	Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys. <i>Molecular Biotechnology</i> , 1998, 10, 115-122.	1.3	8
58	Role of Cross-Linking Agents in Determining the Biochemical and Pharmacokinetic Properties of Mgr-Clavin Immunotoxins. <i>Bioconjugate Chemistry</i> , 1998, 9, 372-381.	1.8	15
59	THE rhGM-CSF-EPO HYBRID PROTEIN MEN 11300 INDUCES ANTI-EPO ANTIBODIES AND SEVERE ANAEMIA IN RHESUS MONKEYS. <i>Cytokine</i> , 1998, 10, 964-969.	1.4	24
60	Expression and characterization of a mouse/human chimeric antibody specific for EGF receptor. <i>Journal of Biotechnology</i> , 1996, 52, 51-60.	1.9	3
61	Clavin, a Type-1 Ribosome-Inactivating Protein from <i>Aspergillus clavatus</i> IF0 8605. cDNA Isolation, Heterologous Expression, Biochemical and Biological Characterization of the Recombinant Protein. <i>FEBS Journal</i> , 1996, 239, 272-280.	0.2	28